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The amikacin plus gentamicin-containing SuperAminoglycoside mediumwas developed for screening multiple-
aminoglycoside resistance in Gram-negative bacteria (Enterobacteriaceae, Pseudomonas aeruginosa, and
Acinetobacter baumannii). It was evaluated using aminoglycoside-susceptible (n=12) and aminoglycoside-
resistant (n=59) Gram-negative isolates, including 16S rRNA methylase producers (n=20). Its sensitivity and
speciﬁcity of detection were, respectively, of 95% and 96% for detecting multiple aminoglycoside-resistant meth-
ylase producers.
Multidrug resistance is now observed increasingly in nosocomial
and community-acquired pathogensworldwide. These bacteria possess
multiple resistancemechanisms, thus nullifyingmost of themajor anti-
biotic classes such as the β-lactams and aminoglycosides. Considering
the wide diffusion of extended-spectrum β-lactamase–producing en-
terobacterial isolates currently observed worldwide (Poirel et al.,
2012), there is a signiﬁcant need to rely on the use of aminoglycosides
to treat infections caused by those multidrug-resistant isolates. There-
fore, identifying and monitoring those isolates exhibiting resistance to
aminoglycosides are of signiﬁcant concern.
The most prevalent mechanisms of resistance to aminoglycosides
(AG) in Enterobacteriaceae are nucleotidyltransferases (ANT),
phosphotransferases (APH), and acetyltransferases (AAC) enzymes
that modify the structures of AG (Ramirez and Tolmasky, 2010). Those
enzymes are usually plasmid-encoded and may be co-associated in
some isolates. However, they usually do not confer cross resistance to
all AG molecules.
On the other hand, plasmid-mediated 16S rRNA methylases confer-
ring a high level of resistance tomultiple AG are also reported (Doi et al.,
2016). Those enzymes methylate the 16S rRNA, which is the intracellu-
lar target of the AG. The 16S rRNAmethylases described in Enterobacte-
riaceae are ArmA, RmtB to RmtH, and NpmA (only a single isolate
reported so far for that latter enzyme). The ArmA methylase is the
most frequently identiﬁed (Doi et al., 2016; Zhou et al., 2010). Those
methylases confer resistance to almost all AG (amikacin, gentamicin,
tobramycin, and kanamycin, except neomycin and apramycin), al-
though NpmA confers additionally resistance to neomycin (given as a
topical agent) and to apramycin (only used in veterinary medicine)
(Wachino et al., 2007). They have been identiﬁed in Enterobacteriaceae,
Acinetobacter baumannii, and Pseudomonas aeruginosa.
Taking into account the signiﬁcance of a potential spread of 16S
rRNA methylases, our aim was to develop a selective culture medium
for screening multiple aminoglycoside-resistant bacteria in human
and animal isolates.
1. Material and methods
The necessity for that medium to prevent contamination by Gram
positives and fungiwas taken in account. Based on our experience of de-
velopment of several screening media, the optimal screening medium
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retained was based on the Eosine-Methylene-Blue (EMB) medium
(product no. 70186; EMB Fluka, Saint-Louis, MO) that is selective for
Gram negatives (Levine, 1943). This medium may also contribute to
species identiﬁcation by differentiating lactose fermenters (black colo-
nies) from most of the nonfermenters (colorless or light lavender).
Since 16S rRNA methylase producers systematically exhibit high-
level resistance to both amikacin and gentamicin, which is very rarely
the case for isolates producing one or more aminoglycoside-modifying
enzymes, those two antibiotics were chosen as selective markers in
our medium. The optimal ﬁnal concentration of amikacin and gentami-
cin (Sigma Aldrich, St. Louis, MO) was 30 μg/mL each taking into ac-
count the MIC cutoff values of amikacin and of gentamicin of
susceptible and resistant strains (see below). Vancomycin (Sigma)
was added as anti–Gram-positive molecule at a ﬁnal concentration of
10 μg/mL, and amphotericin B (Bristol-Myers-Squibb, Rueil-
Malmaison, France) was added as anti-fungi molecule at a ﬁnal concen-
tration of 5 μg/mL. Cultures were incubated at 37°C during 18 h. When
no growth was observed after 18 h, incubation was extended up to 48
h to deﬁnitely assess that no growth actually occurred.
The instructions for the preparation of the stock solutions of
amikacin, gentamicin, vancomycin, and amphotericin B are indicated
in Table 1. According to our observations, the stock solutions may be
kept at−20°C during 1 year. For preparing the SuperAminoglycoside
medium, the diluted powder of EMB was autoclaved at 121°C for 15
min. After cooling the EMB medium for 1 h at 56°C, the antibiotic
stock solutions were added (Table 1). Poured plates were stored at
4°C and protected from direct light exposure before use.
A total of 69 isolates of various species (Enterobacteriaceae,
P. aeruginosa, and A. baumannii) were tested in this study to evaluate
the performance of the SuperAminoglycoside medium (Table 2).
Twelve isolates were susceptible to aminoglycosides, and 57 isolates
were resistant to aminoglycosides (Table 2). The AG-resistant isolates
were characterized at the molecular level for their resistance mecha-
nism (Berçot et al., 2011). Twenty isolates produced 16S rRNA methyl-
ases, and 37 isolates produced aminoglycoside-modifying enzymes. A
single isolate was a recombinant strain producing NpmA. The recombi-
nant plasmid (pNpmA) was constructed by amplifying by polymerase
chain reaction a DNA fragment containing the entire npmA gene with
primers NpmA-Fw-HindIII (5′-ATATAAAGCTTGGCCAGTTATGGTAAAAT
AG-3′) and NpmA-Rv-BamHI (5′-ATATATGGATCCAAACAAAGAAATTG
CTATAACC-4′) from recombinant plasmid pMCL-BE (Wachino et al.,
2007) followed by its cloning into pACYC184 cloning vector giving rise
to plasmid pFR2000 and its expression into Escherichia coli TOP10.
MICs of amikacin and gentamicin were determined using the broth
microdilution method in cation-adjusted Mueller–Hinton broth, as rec-
ommended by the CLSI (CLSI, 2012). For each strain, an inoculum corre-
sponding to 5 × 105 CFU/mL was distributed in the 96-well tray
(Sarstedt, Nümbrecht, Germany). E. coli ATCC 25922 and P. aeruginosa
ATCC 27853 were used as control strains (CLSI, 2014), and the evalua-
tion of the selective medium was performed in triplicate.
According to the CLSI breakpoints (CLSI, 2014), Enterobacteriaceae,
P. aeruginosa, and A. baumannii isolates with MICs of gentamicin ≤4
and of amikacin ≤16 μg/mL are categorized as susceptible, while those
withMICs of gentamicin ≥16 and of amikacin ≥64 μg/mL are categorized
as resistant.
2. Results
Using an inoculumwith an optical density of 0.5 Mac Farland (inoc-
ulumof ~108 CFU/mL), serial 10-fold dilutions of the isolatesweremade
in normal saline, and 100-μL portions were plated onto the
SuperAminoglycoside medium.
To quantify the viable bacteria in each dilution, Trypticase soy agar
was inoculated concomitantly with 100 μL of suspension and incubated
overnight at 37°C. The lowest limit of detection for the tested strains
was determined using the SuperAminoglycosidemedium. The sensitiv-
ity and speciﬁcity cutoff values were set at 1 × 103 CFU/mL, i.e., a limit
value of 1 × 103 CFU/mL and above was considered as “not efﬁciently
detected” (Nordmann et al., 2012).
The lowest limit of detection was above the cutoff value of 103 CFU/
mL, being ≥1 × 106 CFU/mL for all the aminoglycoside-susceptible iso-
lates and for the isolates producing aminoglycoside-modifying enzymes
(Table 2). On the contrary, the 16S rRNA methylase producers grew on
the SuperAminoglycoside medium in 24 h, and the lowest limit of de-
tection was below the cutoff value, except for the E. coli TOP10 isolate
that produced NpmA (Table 2). Of note, two E. coli isolates that did
not produce 16S rRNA methylases (HCSC-Ec22 and HCSC-Ec296) grew
on the SuperAminoglycoside medium. This was somehow expected
when considering that those isolates producing aminoglycoside-
modifying enzymes exhibited high MIC values of both amikacin and
gentamicin (Table 2). The high level of resistance to amikacin and gen-
tamicin observed for those two isolates likely resulted from the produc-
tion of aminoglyside-modifying enzymes (as indicated in Table 2) and
possibly of permeability defects.
The sensitivity and speciﬁcity of the SuperAminoglycoside medium
for selecting amikacin- and gentamicin resistant isolates producing
16S rRNA methylases were consequently 95% (19/20) and 96% (2/49),
respectively, although a limited number of strains have been tested
(Lopez-Diaz et al., 2017). When considering detection of amikacin-
and gentamicin-resistant isolates only (regardless of production of 16S
rRNA methylases), the speciﬁcity of the medium was 100%.
Similar results were obtained by using a Drigalski-containing medi-
um or with other AG combination or AG concentration (data not
shown). Spiked stools were also tested using this selective culture me-
dium, done in triplicate. Spiked fecal samples were made by adding
100 μL of each strain dilution to 900 μL of fecal suspension that was ob-
tained by suspending 5 g of freshly pooled feces from ﬁve healthy vol-
unteers in 50 mL of distilled water, as done previously (Nordmann
et al., 2016). A nonspiked fecal suspensionwas used as negative control.
The lowest detection limit was determined by plating 100 μL of each di-
lution on the screeningmedium. The sensitivity and speciﬁcitywere de-
termined using the same cutoff value set at ≥103 CFU/mL (Nordmann
et al., 2016). This value may correspond to a low-level carriage of resis-
tant bacteria in stools. Sensitivity and speciﬁcity were similar to those
found by using pure cultures of the strains, i.e., 96% and 96%, respective-
ly. The spiked 16S rRNA methylase producers (except the NpmA pro-
ducer) in stools grew with a lowest detection limit ranging from 101
to 102 CFU/mL (Table 2).
To assess the storage stability of the SuperAminoglycoside medium,
C. albicans, S. aureus, and AG-susceptible E. coli ATCC 25922,
K. pneumoniae R437, E. cloacae R713, and P. aeruginosa R191 were
subcultured on a daily basis onto the SuperAminoglycoside agar plates
from a single batch of medium stored at 4°C. Growth of those isolates
was consistently inhibited during at least a 7-day period.
Table 1
Composition of the SuperAminoglycoside medium.
Compound Stock solution
(mg/mL)
Quantity or volume
to adda
Final
concentrationb
EMB agar powder - 15 g 3.75%
Distilled water - 400 mL
Gentamicin 30 in distilled water 400 μL 30
Amikacin 30 in distilled water 400 μL 30
Vancomycin 20 in distilled water 200 μL 10
Amphotericin B 2 in D(+)-glucose 10% 100 μL 5
a The volume of 400 mL of mediumwas for 20 plates, considering plates of 100 mm
diameter.
b Concentrations are in micrograms per milliliter unless noted otherwise.
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Table 2
MICs of amikacin and gentamicin for the studied strains and limit of detection of the aminoglycoside-containing culture medium EMB 30/30.a
Strain Species Mechanism of
aminoglycoside
resistance
MIC (μg/mL) of
antibioticsb
Lowest
detection
limit (CFU/mL)c
Lowest
detection
limit in stools
(CFU/mL)c
Amikacin Gentamicin
Susceptible strains
R2298 E. coli ATCC
25922
- 2 1 N1 × 108 N1 × 108
R2278 E. coli ATCC
35218
- 4 1 N1 × 108 N1 × 108
R1436 E. coli - 2 1 N1 × 108 N1 × 108
R1438 E. coli - 2 1 N1 × 108 N1 × 108
R347 K. pneumoniae - 4 0.5 N1 × 108 N1 × 108
S155 K. pneumoniae - 2 0.5 N1 × 108 N1 × 108
R1433 E. cloacae - 4 2 N1 × 108 N1 × 108
R713 E. cloacae - 4 0.5 N1 × 108 N1 × 108
HM E. cloacae - 4 2 N1 × 108 N1 × 108
R2260 P. mirabilis - 4 4 N1 × 108 N1 × 108
R1395 A. baumannii - 2 1 N1 × 108 N1 × 108
R191 P. aeruginosa - 8 2 N1 × 108 N1 × 108
Aminoglycoside-resistant and non–methylase-producing
strains
pWP701 E. coli AAC(3)-IV 1 128 9 × 107 N1 × 108
pFCT4392 E. coli AAC(3)-Ia 1 32 3 × 107 N1 × 108
390 E. coli AAC(3)-IV 8 64 N1 × 108 N1 × 108
HCSC-Ec90 E. coli AAC(3)-IIa 4 64 N1 × 108 N1 × 108
22089 E. coli AAC(3)-I + AAC(3)-V 8 64 N1 × 108 N1 × 108
97 E. coli AAC(3)-IV 2 32 N1 × 108 N1 × 108
92/31 E. coli AAC(3)-IV 4 16 N1 × 108 N1 × 108
4000 E. coli APH(3’)-I + AAC(3)-V 4 64 N1 × 108 N1 × 108
pFCT1163 E. coli AAC(6’)-Ia 128 4 1 × 108 N1 × 108
1054a E. coli AAC(6’)-I 8 8 N1 × 108 N1 × 108
HCSC-Ec235 E. coli AAC(6’)-Ib 8 8 N1 × 108 N1 × 108
HCSC-Ec296 E. coli AAC(6’)-Ib 32 128 3 × 102 3 × 102
1488 E. coli AAC(6’)-II 4 16 N1 × 108 N1 × 108
1054b E. coli AAC(6’)-I 16 8 N1 × 108 N1 × 108
RP4 E. coli APH(3’)-Ib 1 2 7 × 107 N1 × 108
HCSC-Ec52 E. coli AAC(6’)-Ib + APH(3’)-Ia 8 64 N1 × 108 N1 × 108
122971 E. coli ANT(2”) 4 128 N1 × 108 N1 × 108
HCSC-Ec22 E. coli AAC(6’)-Ib + AAC(3)-IIa 64 64 2 × 102 3 × 102
HCSC-Ec28 E. coli AAC(6’)-Ib + ANT(2”)-Ia 8 32 N1 × 108 N1 × 108
HCSC-Ec30 E. coli AAC(3)-IIa + ANT(2”)-Ia 4 64 N1 × 108 N1 × 108
HCSC-Ec33 E. coli AAC(3)-IIa + APH(3’)-Ia 2 64 N1 × 108 N1 × 108
HCSC-Ec78 E. coli ANT(2”)-Ia + APH(3’)-Ia 2 128 N1 × 108 N1 × 108
HCSC-Ec246 E. coli AAC(6’)-Ib + ANT(2”)-Ia 8 32 N1 × 108 N1 × 108
1800 K. pneumoniae AAC(6')-I + AAC(3)-I 32 16 1 × 108 N1 × 108
13000 K. pneumoniae APH(3’)-I + AAC(3)-V 0.5 128 N1 × 108 N1 × 108
22233 K. pneumoniae AAC(3)-V 16 32 N1 × 108 N1 × 108
1110 E. cloacae ANT(2”) 1 32 N1 × 108 N1 × 108
BM2667 P. stuartii APH(3’)-VI + AAC(2’) 64 8 1 × 108 N1 × 108
531 P. rettgeri AAC(2’) 16 4 6 × 107 N1 × 108
4290 S. marcescens AAC(3)-I 4 64 4 × 107 N1 × 108
BM2580 A. baumannii APH(3’)-VI 64 2 N1 × 108 N1 × 108
8541 A. baumannii APH(3’)-VI 128 0.5 N1 × 108 N1 × 108
4996 A. baumannii AAC(6’)-I 64 4 1 × 108 N1 × 108
3656 P. aeruginosa APH(3’)-I + ANT(4’)-II 128 8 5 × 107 N1 × 108
3658 P. aeruginosa APH(3’)-I + ANT(4’)-II N128 4 N1 × 108 N1 × 108
28233 P. aeruginosa APH(3’)-I + AAC(3)-I 4 1 N1 × 108 N1 × 108
3655 P. aeruginosa APH(3’)-I + ANT(2”) 1 4 N1 × 108 N1 × 108
16S rRNA methylase-producing strains
pFR2000 E. coli TOP10 NpmA 64 32 1 × 107 1 × 107
R989 E. coli ArmA N512 N256 2 × 101 1 × 102
R1012 E. coli ArmA N512 N256 1 × 101 3 × 101
62Carb E. coli RmtB N512 N256 2 × 102 2 × 102
E28 E. coli RmtB N512 N256 4 × 101 4 × 101
R107 E. coli RmtB N512 N256 2 × 101 2 × 101
R990 E. coli RmtB N512 N256 2 × 101 1 × 101
R262 E. coli RmtC N512 N256 3 × 102 3 × 102
R451 E. coli RmtC N512 N256 3 × 101 2 × 101
R500 K. pneumoniae ArmA N512 N256 2 × 102 2 × 102
R108 K. pneumoniae ArmA N512 N256 4 × 101 2 × 101
R2257 K. pneumoniae ArmA N512 N256 1 × 101 2 × 101
N34 K. pneumoniae RmtC N512 N256 3 × 101 1 × 102
R502 K. pneumoniae RmtF N512 N256 2 × 102 3 × 102
R2160 K. pneumoniae RmtG N512 N256 3 × 102 3 × 102
R2258 E. cloacae ArmA N512 N256 2 × 101 2 × 101
R265 P. stuartii RmtC N512 N256 3 × 102 3 × 102
R38 P. stuartii RmtC N512 N256 2 × 101 1 × 101
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3. Discussion
Wedeveloped here the very ﬁrst selectivemedium allowing screen-
ing and detection of Gram-negative bacteria exhibiting high-level resis-
tance to aminoglycosides, in particular 16S rRNA methylase producers.
Those latter strains tend to emerge in different parts of the world, and
it is necessary to use such a medium to perform prospective screening
and epidemiological surveys.
The SuperAminoglycoside mediummay detect not only 16S rRNA
methylase producers but also the very rare isolates being resistant to
both gentamicin and amikacin due to the combination of
aminoglycosides-modifying enzymes or to speciﬁc aminoglycoside-
modifying enzymes. For example, AAC(6’)-Ib with Leu118 and
Ser119 confers a high level of resistance to both gentamicin and
amikacin (Casin et al., 2003). Failure to detect the NpmA producer
tested was noticeable. However, i) the isolate tested was a recombi-
nant strain, and MIC values of amikacin and gentamicin for this
isolate were at the limit of the resistance cutoff value; ii) the resis-
tance level to gentamicin and amikacin of the NpmA-producing clin-
ical isolate is much higher (Wachino et al., 2007) and likely to be
detected by the SuperAminoglycoside medium; and iii) NpmA pro-
ducers seem to be exceptional (just a single NpmA producer report-
ed so far) (Wachino et al., 2010). Overall, this medium offers the
possibility to select for those multiple-aminoglycoside–resistant En-
terobacteriaceae, P. aeruginosa, and A. baumannii from pure culture
as well as from stools. It is foreseeable that similar results would be
obtained by using rectal swabs as starting specimens. This medium
contributes to species identiﬁcations according to the color of the
colonies growing on the medium (Fig. 1A and B) and is able to differ-
entiate several bacterial species growing on the medium.
The use of this selective medium may contribute to rapidly identify
carriers of multidrug-resistant isolates producing plasmid-mediated
16S rRNA methylases and consequently to rapidly implement infection
control measures in order to limit their spread. It may be useful in par-
ticular in the context of the spread of NDM-type carbapenemase
producers since NDM and 16S rRNA methylases are often associated
(Lopez-Diaz et al., 2017; Poirel et al., 2011; Rahman et al., 2015). Finally,
this medium may be also interesting for screening the environmental
and animal reservoirs for 16S rRNA methylase producers. Indeed,
those resistance traits have been already identiﬁed in chicken for
which aminoglycoside use may represent a selective driving force
(Yang et al., 2015).
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